Shilpa Medicare gets USFDA EIR for Raichur API Unit
Advertisement
Raichur: Shilpa Medicare Limited has announced the receipt of Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur, Karnataka, India during the period between "03rd February and 07th February 2020". USFDA has determined that the inspection classification of this facility is "NO ACTION INDICATED" ("NAI").
Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India.
The commercial production in the SML was started in November 1989.
Read also: Shilpa Medicare Launches Breakthrough Therapy Lenvatinib Mesylate Under Brand Lenshil In India
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.